Significant Ownership of Rosalind Advisors, Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Rosalind Advisors, Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- Steven Salamon - President
- Manager location
- Toronto
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Rosalind Advisors, Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Rosalind Advisors, Inc.
Significant Ownership of Rosalind Advisors, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| DCTH | DELCATH SYSTEMS, INC. | DELCATH SYSTEMS, INC. | 9.9% | $70,022,327 | +$468,900 | 6,719,993 | +0.67% | Rosalind Advisors, Inc. | 31 Dec 2025 |
| PYPD | PolyPid Ltd. | Common Shares | 9.9% | $26,798,578 | -$1,363,994 | 5,124,011 | -4.8% | Rosalind Advisors, Inc. | 31 Jul 2026 |
| BFRI | Biofrontera Inc. | Common Shares | 9.9% | $19,153,857 | +$698,647 | 16,801,629 | +3.8% | Rosalind Advisors, Inc. | 30 Jun 2026 |
| FEMY | FEMASYS INC | Common Shares | 9.9% | $16,265,625 | 4,687,500 | Rosalind Advisors, Inc. | 10 Aug 2026 | ||
| TLPH | TALPHERA, INC. | Common Shares | 9.9% | $15,237,555 | -$280,571 | 12,913,182 | -1.8% | Rosalind Advisors, Inc. | 30 Jun 2026 |
| MYO | MYOMO, INC. | Common Shares | 9.9% | $8,141,258 | -$222,075 | 7,401,144 | -2.7% | Rosalind Advisors, Inc. | 30 Jun 2026 |
| REGENTIS BIOMATERIALS LTD. | Common Shares | 9.9% | 1,428,570 | Rosalind Advisors, Inc. | 30 Jun 2026 | ||||
| KPRX | KIORA PHARMACEUTICALS INC | Common Shares | 9.9% | 464,676 | 0% | Rosalind Advisors, Inc. | 31 Dec 2025 | ||
| FENC | FENNEC PHARMACEUTICALS INC. | Common Shares | 9.6% | $35,704,330 | +$3,007,850 | 3,321,333 | +9.2% | Rosalind Advisors, Inc. | 30 Jun 2026 |
| NSPR | InspireMD, Inc. | Common Shares | 9.2% | $19,557,045 | 10,987,104 | 0% | Rosalind Advisors, Inc. | 31 Dec 2025 | |
| MDWD | MediWound Ltd. | Common Shares | 7% | 912,319 | 0% | Rosalind Advisors, Inc. | 31 Dec 2025 | ||
| CLRB | Cellectar Biosciences, Inc. | Common Shares | 5.5% | 247,715 | -97% | Rosalind Advisors, Inc. | 31 Dec 2025 | ||
| TRVI | Trevi Therapeutics, Inc. | Common Shares | 1.2% | $6,746,875 | 1,062,500 | Rosalind Advisors, Inc. | 13 Feb 2025 | ||
| OPTN | OptiNose, Inc. | Common Shares | 0% | $0 | -$3,128,407 | 0 | -100% | Rosalind Advisors, Inc. | 30 Jun 2025 |
| SPRB | SPRUCE BIOSCIENCES, INC. | Common shares | 0% | $0 | 0 | Rosalind Advisors, Inc. | 31 Dec 2024 |
Schedules 13D/G Reported by Rosalind Advisors, Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.